Biocon enters Latin American market with Libbs Farmaceutica tie-up

Biocon Limited announced that its unit Biocon Pharma has tied up with Brazil-based pharmaceutical company Libbs Farmaceutica to launch its generic drug formulations in the country. This arrangement is subject to the approval from Brazil's health regulatory agency ANVISA. In 2017, the global biopharmaceutical company launched a biosimilar targeted cancer drug Trastuzumab in Brazil with Libbs.